Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:15:43.086Z.
Consensus retrieved: 2026-10-06T08:54:07.148Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:15:43.086Z.
Quote observation: 2026-10-06T14:11:29.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d88ebff11657cb0645ea93f74423bc241bf41286751ec96f31399ab1bd3406dc
Forward PE Ratio (N/A) = Dated Quote Price ($0.67) / Consensus Forward EPS ($-0.29)
FORWARD PE RATIO
N/A
Aprea Therapeutics, Inc.
Market Cap
$8.29M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.29M | N/A |
| DataMEDS AI, Inc. (MEDS)vs › | $8.47M | N/A |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.48M | N/A |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.89M | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.84M | N/A |
| HeartSciences Inc. (HSCS)vs › | $7.78M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.46M | N/A |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $9.14M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.36M | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.67, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.29 | $-0.33 – $-0.24 | 2 | n/m |
| 2027-12-31 | $-0.29 | $-0.44 – $-0.14 | 2 | n/m |
| 2028-12-31 | $-0.35 | $-0.37 – $-0.31 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
